Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.
Losing weight with GLP-1 drugs is only half the battle. Keeping it off long term has proved even harder.
Factors such as side effects, high out-of-pocket costs, injection fatigue and stigma around o… [+12838 chars]
Discussion (0)
No comments yet. Be the first to share your thoughts!
Join the Conversation
You need to be logged in to leave a comment.
Sign In Create Account